Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction

Glioblastoma is a primary brain tumor associated with a poor prognosis due to its high chemoresistance capacity. Cancer stem cells (CSCs) are one of the mechanisms of chemoresistance. Although therapy targeting CSCs is promising, strategies targeting CSCs remain unsuccessful. Abnormal activation of...

Full description

Bibliographic Details
Main Authors: Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka, Masashi Okada
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
glioma stem cell
glioblastoma
brexpiprazole
osimertinib
survivin
xenograft
Online Access:https://www.mdpi.com/2072-6694/11/7/947

Internet

https://www.mdpi.com/2072-6694/11/7/947

Similar Items